Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Side Effect of Drug Clear all
Not listed No phase listed Observational

Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations

NCT04378881
View directory record Official record
Conditions
COVID, Drug Effect, Drug Interaction, Adverse Drug Event
Interventions
Not listed
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Jul 22, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

NCT00019864
View directory record Official record
Conditions
Cardiac Toxicity, Sarcoma
Interventions
filgrastim, cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, leucovorin calcium, methotrexate, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
4
States / cities
Bethesda, Maryland • Oklahoma City, Oklahoma • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Results available

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110
View directory record Official record
Conditions
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Jul 22, 2026, 8:15 PM EDT
Recruiting Phase 4 Interventional

The STOP-MED CTRCD Trial

NCT06183437
View directory record Official record
Conditions
Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions
Stopping Heart Failure Medication(s)
Other
Lead sponsor
Dinesh Thavendiranathan
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantifying the Attentive Behaviors of Older Adults During Over-the-counter Drug Selection

NCT02188134
View directory record Official record
Conditions
Older Adults (65 Years and Older)
Interventions
Not listed
Lead sponsor
Michigan State University
Other
Eligibility
65 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 22, 2026, 8:15 PM EDT
Not listed Phase 1Phase 2 Interventional

Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00004264
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions
amifostine trihydrate, cisplatin, docetaxel
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

NCT00039481
View directory record Official record
Conditions
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, filgrastim, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Jul 22, 2026, 8:15 PM EDT
Withdrawn Phase 4 Interventional

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

NCT06107829
View directory record Official record
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Valbenazine Oral Capsule
Drug
Lead sponsor
Stephen Ruedrich
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil

NCT01219023
View directory record Official record
Conditions
Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
Interventions
sildenafil citrate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Jul 22, 2026, 8:15 PM EDT
Completed No phase listed Observational

Early Detection of Broken Hearts in Cancer Patients

NCT02086695
View directory record Official record
Conditions
Cardiotoxicity
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 22, 2026, 8:15 PM EDT
Not listed No phase listed Observational

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines

NCT03155802
View directory record Official record
Conditions
Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy, Biomarkers, Echocardiography
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Implementation of Real-time ADE Surveillance and Decision Support

NCT00780572
View directory record Official record
Conditions
Adverse Drug Events
Interventions
ADE alert assistant
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

NCT03461445
View directory record Official record
Conditions
Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
Interventions
Envarsus, IR Tacrolimus
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
60 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

Vestibular Implantation in Older Adults

NCT05676944
View directory record Official record
Conditions
Other Disorders of Vestibular Function, Bilateral, Bilateral Vestibular Deficiency (BVD), Gentamicin Ototoxicity, Labyrinth Diseases, Vestibular Diseases, Sensation Disorders, Bilateral Vestibular Hypofunction, Bilateral Vestibulopathy, Presbyvestibulopathy, Aminoglycoside Ototoxicity
Interventions
Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 8:15 PM EDT
Completed No phase listed Observational Results available

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

NCT03223428
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Xermelo
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs

NCT00797407
View directory record Official record
Conditions
Hypercholesterolemia, Aches, Cramps, Weakness
Interventions
Creatine
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Wooster, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2008 · Synced Jul 22, 2026, 8:15 PM EDT
Terminated Not applicable Interventional

Aerobic Exercise in Patients Receiving Chemotherapy for Cancer

NCT00728429
View directory record Official record
Conditions
Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
exercise intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

NCT00118339
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
chemoprotection, complementary or alternative medicine procedure, management of therapy complications
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Jul 22, 2026, 8:15 PM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jul 22, 2026, 8:15 PM EDT
Not listed No phase listed Observational

Genetics of QT Prolongation With Antiarrhythmics

NCT02439658
View directory record Official record
Conditions
Long QT Syndrome, Drug Toxicity
Interventions
Dofetilide and/or sotalol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 22, 2026, 8:15 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users

NCT02945293
View directory record Official record
Conditions
Mild to Heavy Alcohol Consumption
Interventions
Oxycodone
Other
Lead sponsor
University of Washington
Other
Eligibility
35 Years and older
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 22, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

NCT01135680
View directory record Official record
Conditions
Drug Toxicity
Interventions
HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 22, 2026, 8:15 PM EDT